Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tumors. Found 95 abstracts

no pagination
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Simhan J, Canter DJ, Sterious SN, Smaldone MC, Tsai KJ, Li TY, Viterbo R, Chen DY, Greenberg RE, Kutikov A, Uzzo RG. Pathological Concordance and Surgical Outcomes of Sporadic Synchronous Unilateral Multifocal Renal Masses Treated with Partial Nephrectomy. Journal of Urology. 2013 Jan;189(1):43-7.
Bodurka DC, Deavers MT, Tian CQ, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system. Cancer. 2012 Jun;118(12):3087-94.   PMCID: *
Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong CY, Hittelman WN, Wen XX, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity. Molecular Cancer Therapeutics. 2012 Jan;11(1):143-53.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 2012 Nov;127(2):345-50.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 2012 Nov;127(2):345-50.   PMCID: PMC3518448
Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou XF, Danaee H, Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic Oncology. 2012 Oct;127(1):63-9.   PMCID: Not NIH Funded
Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology. 2012 Jun;33(3):617-27.   PMCID: not NIH funded
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 2012 Mar;124(3):563-8.   PMCID: PMC3278517
Reyes JM, Canter DJ, Sirohi M, Simhan J, Smaldone MC, Teper E, Kutikov A, Chen DY, Uzzo RG. Delayed proximal ureteric stricture formation after complex partial nephrectomy. BJU international. 2012 Feb;109(4):539-43.
Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Oncotargets and Therapy. 2012 Jan;5:161-70.   PMCID: PMC3430391
Simhan J, Smaldone MC, Tsai KJ, Li TY, Reyes JM, Canter D, Kutikov A, Chen DY, Greenberg RE, Uzzo RG, Viterbo R. Perioperative Outcomes of Robotic and Open Partial Nephrectomy for Moderately and Highly Complex Renal Lesions. J Urol. 2012 Jun;187(6):2000-4.
Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 2012 Nov;18(21):6023-31.
von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb;118(3):770-6.   PMCID: PMC3576704
Adams SF, Marsh EB, Elmasri W, Halberstadt S, VanDecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC, Belsadron G, Biochimie V P. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecologic Oncology. 2011 Dec;123(3):486-91.   PMCID: PMC3260049
Fukata M, Shang LM, Santaolalla R, Sotolongo J, Pastorini C, Espana C, Ungaro R, Harpaz N, Cooper HS, Elson G, Kosco-Vilbois M, Zaias J, Perez MT, Mayer L, Vamadevan AS, Lira SA, Abreu MT. Constitutive Activation of Epithelial TLR4 Augments Inflammatory Responses to Mucosal Injury and Drives Colitis-associated Tumorigenesis. Inflammatory Bowel Diseases. 2011 Jul;17(7):1464-73.   PMCID: PMC3117047 [Available on 2012/7/1]
Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Evans DG, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu YA, Hunter-Schaedle K, Giancotti FG. Back to the Future: Proceedings From the 2010 NF Conference. American Journal of Medical Genetics Part A. 2011 Feb;155A(2):307-21.   PMCID: PMC3079924
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus. Cancer. 2011 Apr;117(7):1409-14.   PMCID: PMC3116987
Simhan J, Smaldone MC, Tsai KJ, Canter DJ, Li TY, Kutikov A, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Objective Measures of Renal Mass Anatomic Complexity Predict Rates of Major Complications Following Partial Nephrectomy. European Urology. 2011 Oct;60(4):724-30.   PMCID: PMC3319121
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Som G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast Cancer: Noninvasive and Special Situations. Journal of the National Comprehensive Cancer Network. 2010 Oct;8(10):1182-207.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tumors

tumors expression carcinoma nephron-sparing surgery factor receptor solid cohort cancer lung-cancer chronic kidney-disease her2 gefitinib survival mutations Epidermal growth factor receptor Endometrial cancer-Mutation-Lapatinib-Tyrosine kinase inhibitor cell carcinoma kinase inhibitor trends endothelial growth-factor phase-ii monoclonal-antibody outcomes combination pik3ca mutations progression Ovarian cancer trial cell advanced breast-cancer growth-factor receptor epidermal-growth-factor in-vivo BRCA mutations recognition kidney cancer neurofibromatosis type-2 Ovarian cancer Aurora A kinase-MLN8237-Platinum-refractory-Platinum-resistant guidelines carcinoma kidney-renal cell-neoplasms-multiple primary-nephrectomy-pathology-surgical radical tamoxifen receptor beta-subunit cell death animal toxicity analysis complications colorectal neoplasia enzyme fusion masses toll-like receptor-4 breast-cancer growth 2002 llo sp-biol chem-v383-p69 prognosis antiangiogenic therapy marker radical nephrectomy promotes concurrent capecitabine tumorigenesis Partial nephrectomy mutational kinase peripheral-nerve ulcerative-colitis noninvasive breast ca125 response criteria taxol hemangiopericytoma experience squamous cancer esophageal cancer-erlotinib-response evaluation topotecan classification pagets-disease pichia-pastoris laparoscopic radical prostatectomy cancer patients NCCN Guidelines angiosarcoma platinum model pegylated liposomal doxorubicin epidemiology Complications radiation therapy innate immunity NCCN Clinical Practice Guidelines surgical adjuvant breast proximal ureteric stricture gastroesophageal junction spred1 oophorectomy protein farnesyltransferase radiation-therapy bowel-disease positron-emission-tomography HER2 Diabody-Pichia-E coli-PET imaging clonal ulcerative colitis neoplasms paclitaxel pancreas cancer-gemcitabine-irradiation colorectal carcinoma liposarcoma sunitinib universal grading system carcinomas carcinoma-in-situ recombinant immunotoxin cell lung-cancer 1993 oy h-cancer-v71-p3774 tissue resistance chemotherapy schwannomatosis neurofibromatosis-NF1-NF2-neurofibroma-learning disabilities-bone dysplasia-MPNST therapy lobular carcinoma in situ immunogenicity leiomyosarcoma p53 ca 125 induction chemotherapy solitary fibrous tumor american-joint-committee Bevacizumab early prediction partial nephrectomy murine colitis half-life endocrine therapy cancer-therapy glycosylation phyllodes Toll-like receptor braf fv bevacizumab gynecologic-oncology-group phenotype 1995 oe ys-journal of medicinal chemistry-v38-p816 renal-cell carcinoma origin single-chain fv nephrectomy nuys prognostic disease protein fluorouracil tumor marker cm
Last updated on Wednesday, September 06, 2017